Molecular Insights into Leech-Derived Bioactive Compounds: Biochemical Mechanisms and Therapeutic Potential
Review published in International Journal of Molecular Sciences (2026)
Abstract
The bioactive compounds that are produced by leeches combine traditional and modern treatment since the saliva of the animal contains proteins and peptides with anticoagulant, anti-inflammatory, antimicrobial, antioxidant, and regenerative properties. In this review, their biochemical profile, mechanisms and clinical uses are considered with a special focus on the fact that they are utilized to combine traditional practices with the modern developments in biomedical approaches. Proteomic and transcriptomic research has recently found more than 100 bioactive molecules, such as hirudin, calin, eglins, bdellins and destabilase, which are related to the blood-feeding process and therapeutic processes. These compounds control blood clotting, control inflammatory mediators, block microbes and enhance wound healing and the development of new blood vessels. In clinical practice, leech therapy is common in the reconstruction and microsurgical practice to reduce venous congestion and enhance graft success. They are also shown to be useful in wound healing, cardiovascular health, musculoskeletal conditions and regenerative medicine, as well as emerging drug delivery systems of recombinant proteins and nanocarriers. Some of the challenges involve biological variation, infection or bleeding risks and stringent regulations on purity and standardization. Biotechnology has improved through other developments such as recombinant protein production, high-throughput omics, and nanotechnology, which will help resolve these problems, making them safe and scalable for clinical use. Altogether, leech bioactives are the prime examples of the sophisticated pharmacology of nature, which have the potential of being used as therapeutic agents in the future. The recent approach and incorporation in personalized medicine and bioengineering models reflect the leech's capacity to address complicated illness and unmet healthcare requirements to reassert its significance in preventive medicine and recent biomedicine.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Резюме
Comprehensive review of more than 100 leech-derived bioactive molecules (hirudin, calin, eglins, bdellins, destabilase) with biochemical mechanisms, clinical applications in microsurgery and regenerative medicine, and biotechnology-driven scale-up strategies.
Почему это важно для гирудотерапии
This review article covers the biochemical profile, mechanisms, and clinical uses of leech-derived bioactive compounds, noting that proteomic and transcriptomic research has identified more than 100 molecules—including hirudin, calin, eglins, bdellins, and destabilase—with anticoagulant, anti-inflammatory, antimicrobial, antioxidant, and regenerative properties. The abstract discusses clinical applications in reconstructive and microsurgical practice for reducing venous congestion, as well as emerging uses in wound healing, cardiovascular health, musculoskeletal conditions, regenerative medicine, and drug delivery systems using recombinant proteins and nanocarriers. For ASH's domain, this review provides a broad overview of the leech secretome's therapeutic potential and the biotechnological advances addressing challenges of biological variation, infection risk, and standardization. Caveat: this is a review article synthesizing existing literature; the abstract does not present original data, specific clinical trial results, or quantitative efficacy comparisons.
Цитирование
Molecular Insights into Leech-Derived Bioactive Compounds: Biochemical Mechanisms and Therapeutic Potential.
Raghavi S, Deva Darshini B, Saravanan KM, Anbarasu K · International journal of molecular sciences, 2026
Связанный клинический контекст
Узнайте, как это исследование связано с клинической практикой
Добавлено в библиотеку ASH: May 26, 2026 · Последнее обновление сайта: June 18, 2026